TIMELESS

Across TCGA pan-cancer cohorts, TIMELESS Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated TIMELESS data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TIMELESS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TIMELESS expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

MESO, COAD, and STAD are the cancer types where TIMELESS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
COAD	DFS	Median	III,IV	0.234	0.670	.010	12	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	6	view →
UCEC	DFS	Median	All	0.933	0.615	.016	6	view →
LIHC	DFS	Median	II,III,IV	0.094	0.417	.037	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	5	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →
BLCA	DFS	Median	II,III,IV	0.861	0.603	.035	3	view →
SKCM	DFS	Median	III,IV	1.000	0.574	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

TIMELESS–MESO (OS)

Open the MESO breakdown →